CN Patent

CN105017168A — 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]三唑-3-基硫烷基]-乙酸甲酯的新制备方法

Assigned to ANHUI WANBANG MEDICAL TECHNOLOGY Co Ltd · Expires 2015-11-04 · 11y expired

What this patent protects

本发明提供了一种[5-溴-4-（4-环丙基萘-1-基）-4H-[1,2,4]三唑-3-基硫烷基]-？乙酸甲酯的新制备方法及其中间体4-（4-环丙基萘-1-基）-2,4-二氢-[1,2,4]三唑-3-酮，该中间体用于合成抗痛风药Lesinurad，具有经济性、环保性、高效性及产率高等优点，能够大规模的实现工业化生产。

USPTO Abstract

本发明提供了一种[5-溴-4-（4-环丙基萘-1-基）-4H-[1,2,4]三唑-3-基硫烷基]-？乙酸甲酯的新制备方法及其中间体4-（4-环丙基萘-1-基）-2,4-二氢-[1,2,4]三唑-3-酮，该中间体用于合成抗痛风药Lesinurad，具有经济性、环保性、高效性及产率高等优点，能够大规模的实现工业化生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN105017168A
Jurisdiction
CN
Classification
—
Expires
2015-11-04
Drug substance claim
No
Drug product claim
No
Assignee
ANHUI WANBANG MEDICAL TECHNOLOGY Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.